| Company* (Country; Symbol) | Company* (Country; Symbol) | Type/Product Area | Terms/Details (Date) |
| FEBRUARY | |||
| Actelion Ltd. (Switzerland;SWX:ATLG) | GeneraMedix Inc.* | Agreement for Actelion to acquire a new formulationfor epoprostenol sodium for the intravenous treatmentof pulmonary arterial hypertension | Actelion will be responsible for global development, registration and commercialization (2/23) |
| Amarillo Biosciences Inc. (OTC BB:AMAR) | Cyto Biotech Inc.* (Taiwan) | 15-year license and supply deal under which Cyto willconduct all clinical trials and studies and seek regulatory approvals in China, Taiwan,Thailand, the Philippines, Cambodia, Vietnam and Malaysia for Amarillo's low-dose interferon in animaland human health indications | Cyto purchased common stock in Amarillo, paid an initial license fee and willpay a net royalty on product sales (2/26) |
| Argenta Discovery Ltd.* (UK) | Almac Discovery Ltd.*(UK) | Fee-for-service collaboration in which scientists will work toadvance one of Almac's cancer programs from hit identificationto development candidate | Argenta will provide computational chemistry and medicinal chemistryservices, and Almac will contribute medicinal chemistry, biochemistry and invitro screening capabilities and expertise (2/2) |
| Ceapro Inc. (Canada; CDNX:CZO) | IR2Dx Inc.* | Research and commercial development agreement tocompare the oral glucose tolerance test to CeaProvediabetes diagnostic | Terms were not disclosed (2/10) |
| Champions Biotechnology Inc. (OTC BB:CSBR) | Gradalis Inc.* and theMary Crowley Cancer ResearchCenter | Collaboration to develop personalized cancer vaccines | The endeavor will use Champions' Biomerk Tumorgraft technology (2/3) |
| Cypress Bioscience Inc. (CYPB) | Cellatope Corp.* | Agreement for Cypress to acquire a technology platformfrom Cellatope that uses cell-bound complement activation products to diagnose and monitor debilitating autoimmune disorders | Cypress will assume a license from the University of Pittsburgh; terms include a$2M cash payment for the diagnostic technology, as well as an additional $3Mpotential milestone payment (2/24) |
| Defyrus Inc.* | Ploughshare Innovation Ltd.* | Exclusive, worldwide license agreement to a patent portfolio created by the UK's Defense Science and Technology Laboratory | Defyrus and Ploughshare plan to expand their commercial interaction to includepreclinical safety and efficacy studies as part of the firm's vaccine developmentprogram (2/19) |
| Lentigen Corp.* | Expression Therapeutics LLC* | Agreement to codevelop cell and protein therapies for theblood-clotting disorder hemophilia A | They will develop two types of treatments: a chimeric factor VIII protein for direct injection and a cell therapy that may permanently correct the disorder (2/5) |
| Ligand Pharmaceuticals Inc. (LGND) | Trevena Inc.* | Joint research and license alliance to screen targetsusing Trevena's biological platform against Ligand'scombinatorial library of compounds to identify activecompounds with potential for development as novel G-protein coupled receptor therapeutics | Ligand expects to screen 24 targets over two years and receive payments triggeredby a tiered screening paradigm for each target (2/6) |
| Novavax Inc. (NVAX) | Vivalis (France; Paris:VLS) | Research license agreement to use Vivalis' EB66 cell linefor the production of Novavax VLP-basedvaccines against several new potential viruses | Financial terms were not disclosed (2/4) |
| Orexo AB (Sweden: SSE:ORX) | Unnamed health care company | Exclusive development agreement for Orexo's OX17 program for gastroesophageal reflux disease | Orexo will continue negotiations to enter into an appropriate global exclusivelicense agreement (2/9) |
| Pharmos Corp. (PARS) | Reperio Pharmaceuticals Ltd.* (Israel) | Licensing agreement for rights to PRS-639,058 andsome follow-on molecule synthetic compounds | Reperio gains the rights; no financial details were disclosed (2/18) |
| Spectrum Pharmaceuticals Inc. (SPPI) | Cell Therapeutics Inc. (CTIC) | Agreement for Spectrum to take control of Zevalin | Spectrum agreed to buy-out Cell Therapeutics from their joint venture foran additional $18M, after having spent $15M for a 50% interest in RIT OncologyLLC in December (2/23) |
| UCB SA (Belgium; BR:UCB) | Eumedica* (Belgium) | Agreement to sell worldwide rights to UCB's anti-hemorrhagic product Somatostatine-UCB, indicated for acute uppergastrointestinal bleeding resulting from gastric andduodenal ulcers | Financial details were not disclosed (2/10) |
| Xencor Inc.* | CSL Ltd.* (Australia) | Antibody optimization collaboration to provideCSL with access to Xencor's XmAb technology platformto enhance the ADCC effector function of itsantibodies | Xencor will provide CSL with the technology across its antibody candidatepipeline; Xencor is entitled to an up-front payment, milestone payments androyalties (2/23) |
| Xenomics Inc. (PK:XNOM) | Laboratory Corp. of America Holdings (NYSE:LH) and InVivoScribe Technologies* | Nonexclusive license agreement to NPM1 testingfor acute myeloid leukemia | Financial terms were not disclosed (2/25) |
| MARCH | |||
| Advanced Cell Technology Inc. (PK:ACTC) | CHA Bio & Diostech Co. Ltd.* (Korea) | Licensing agreement for its retinal pigment epithelium technology to CHA Bio for the development and commercialization exclusively in Korea of treatments for diseases of the eye | ACT is eligible to receive up to a total of $1.9M in fees based on milestones (3/30) |
| Aphios Corp.* | VivaCell Biotechnology Espana* (Spain) | Collaboration to develop a combination therapy for HIV latency | The companies will evaluate combinations of bryostatin-1 and histone deacetylase inhibitors (3/24) |
| Ascenion GmbH* (Germany) | Inverness Medical Innovations (NYSE:IMA) | Licensing contract giving Inverness worldwide, exclusive rights to an antibiotic for tuberculosis | The compound, a benzothiazinone derivate, is designed to selectively kill mycobacteria at low concentrations, including strains that are resistant against one or more available antibiotics (3/20) |
| AVEO Pharmaceuticals Inc.* | Biogen Idec Inc. (BIIB) | Agreement to develop and commercialize AVEO's discovery-stage ErbB3-targeted antibodies for the potential treatment of cancer and other diseases | AVEO will receive an up-front payment and is eligible for milestones (3/24) |
| Axikin Pharmaceuticals Inc.* | Proteros Fragments GmbH* (Germany) | Research service collaboration to discover customized lead compounds against inflammatory diseases | Proteros will provide research teams with the aim of generating multiple advanced lead series inhibiting a proprietary target protein (3/30) |
| Biovitrum AB (Sweden; SSE:BVT) | Affibody AB* (Sweden) | Agreement to develop targeted therapeutics against inflammation and autoimmune disease | Biovitrum gains access to technology platforms of Affibody molecules, as well as to albumin-binding technology for pharmaceuticals development (3/24) |
| Genavia Therapeutics Ltd.* | Origen Therapeutics Inc.* | Licensing agreement for technology to produce therapeutic proteins in chicken eggs | The patent-protected technology has been shown capable of producing in egg whites therapeutic proteins; Genavia will apply the technology to produce human Factor VIII (3/9) |
| Human Genome Sciences Inc. (HGSI) | Morphotek Inc.* | Deal to discover, develop and commercialize therapeutic monoclonal antibodies in oncology and immunology that specifically target antigens discovered by HGS | Morphotek will be responsible for validating targets, developing all monoclonal antibody candidates using Morphotek technologies and conducting early proof-of-concept studies (3/25) |
| ImmunoCellular Therapeutics Ltd. (OTC BB:IMUC) | Formatech Inc.* | Agreement to develop an optimal formulation for IMUC's cancer stem cell vaccine product candidate ICT-121 | The agreement calls for Formatech to develop a formulation for ICT-121 that allows for long-term stability of the vaccine as well as suitability for intra-dermal injection (3/10) |
| Insmed Inc. (INSM) | IDIS Ltd.* (UK) | Deal to manage expanded access programs worldwide for Insmed's drug Iplex, excluding the U.S. and Italy | Insmed will be responsible for the Iplex EAP for amyotrophic lateral sclerosis in Italy, as well as all Iplex-related activities in the U.S., while IDIS will assume responsibility for the management of all other EAPs worldwide (3/31) |
| International Stem Cell Corp. (OTC BB:ISCO) | Cytograft Tissue Engineering* | Agreement to design a custom cell culture medium to cultivate living human vascular grafts | The living human product, Lifeline, will be used as a coronary graft for coronary bypass procedures, as a peripheral graft to prevent lower limb amputations and as a living tissue shunt for hemodialysis patients (3/12) |
| Intertech Bio* | Oncolin Therapeutics Inc. (PK:OCOL) | Companies reached a tentative agreement for the founding scientist and consultants of Intertech Bio to assume 75% of the outstanding stock in exchange for the assumption of certain liabilities and future obligations associated with the ongoing operations of the subsidiary | Oncolin said it will retain a 25% interest in Intertech (3/6) |
| MultiCell Technologies Inc. (OTC BB: MCET) | Maxim Biotech Inc.* | Partnership to develop reagent tool kits to isolate liver stem cells and elucidate their gene function and encoded proteins | Financial terms were not disclosed (3/19) |
| NovaBay Pharmaceuticals Inc. (AMEX:NBY) | Galderma SA* (Switzerland) | Agreement to develop and commercialize antimicrobial compounds to treat acne and impetigo and other | NovaBay could bank up to $50M if it hits all milestones; it also could get escalating double-digit royalties; it expects to receive $4M in cash this year (3/25) |
| Osiris Therapeutics Inc. (OSIR) | NuVasive Inc. (NUVA) | Agreement to accelerate transfer of the Osteocel business | NuVasive will assume responsibility for Osteocel processing by April 10 and has removed contingencies applicable to $30M of the $45M in remaining milestone payments (3/30) |
| Quest PharmaTech Inc. (Canada; CDNX: QPT) | IntelligentNano Inc.* (Canada) | Alliance to receive a one-year extension for the repayment of its $500,000 convertible debenture | The companies created a water-soluble nano-formulation of Quest's SL-052 technology (3/18) |
| Seegene Inc.* | Randox Laboratories* (UK) | Agreement to obtain a nonexclusive license to Seegene's Dual Priming Oligo technology to develop high-throughput diagnostic screening panels capable of simultaneously detecting a wide variety of infectious pathogens that cause either respiratory or sexually transmitted diseases | Financial terms were not disclosed (3/31) |
| Sunesis Pharmaceuticals Inc. (SNSS) | SARcode Corp.* | Agreement for Sunesis to sell its intellectual property and other assets in its LFA-1 inhibitor program previously licensed to SARcode | It is being sold for $2M in cash (3/9) |
| Symphogen A/S* (Denmark) | Origen Therapeutics* | Collaboration to develop a transgenic chicken capable of producing human antibodies against a wide variety of disease targets | Both companies will provide funding for the development of transgenic, human antibody-expressing chickens using Origen's avian transgenic technology; Origen will receive up-front license payments and further payments upon reaching defined research and development goals; the companies will pay each other royalties (3/6) |
| Ugichem GmbH* (Austria) | Santhera Pharmaceuticals AG (Switzerland; SWX:SANN) | Research and development collaboration to evaluate its oligonucleotide platform technology for potential therapeutics to treat inherited neuromuscular disorders | Santhera has the right to develop such molecules further toward oligonucleotide-based therapeutics (3/23) |
| APRIL | |||
| Aegis Therapeutics LLC* | Phylogica Ltd. (Australia; ASX:PYC) | Collaboration to use Aegis' Intravail transmucosal delivery for Phylogica's Phylomer peptide drugs | Financial terms were not disclosed (4/14) |
| Amylin Pharmaceuticals Inc. (AMLN) and Eli Lilly and Co. | Altea Therapeutics Corp.* | Collaboration for a transdermal version of the drug using Altea's PassPort Transdermal Delivery System | Amylin and Lilly will make an undisclosed up-front cash payment to Altea, in addition to an equity investment; Altea also is eligible for clinical, regulatory and development milestones of up to $46M, plus royalties on future product sales (4/1) |
| Celldex Therapeutics Inc. (CLDX) | Amgen Inc. (AMGN) | Deal giving Celldex rights to two immune-stimulating molecules from Amgen | Celldex gains exclusive rights to develop and market Flt3 and CD40; financial terms were not disclosed (4/9) |
| Cordex Pharma Inc. (OTC BB:CDXP) | BG Medicine Inc.* | Agreement to collaborate in a Phase II safety trial with CDP-1050 in heart failure patients | BGM will measure levels of Galectin-3 in patients enrolled in the study; financial terms were not disclosed (4/8) |
| Emisphere Technologies Inc. (EMIS) | AAIPharma Inc. (PK:AAIIQ) | Alliance to expand the application of Emisphere's Eligen technology and AAI-Pharma's drug development services | The technology is designed to provide an improved delivery method for therapeutic molecules and nutritional supplements and can be applied to oral administration or other routes of administration (4/6) |
| Horizon Discovery Ltd.* (UK) | Genentech Inc. (unit of Roche) | Collaboration to use Horizon's GENESIS gene-engineering platform to develop genetically defined human X-MAN cancer models for Genentech's drug discovery research programs | The renewable three-year deal builds upon four previous business agreements between the companies; the deal includes up-front, milestone and renewal fees (4/2) |
| InterMed Discovery GmbH* (Germany) | Lead Discovery Center GmbH* (Germany) | Collaboration to identify naturally derived modulators by screening IMD's natural product libraries against targets provided by LDC | Financial terms were not disclosed (4/2) |
| OctoPlus NV (the Netherlands; Amsterdam:OCTO) | Undisclosed European biotech company | Drug delivery technology evaluation contract | The deal is part of a plan to develop controlled-release versions of existing or new drugs for clients; OctoPlus will evaluate the feasibility of a controlled-release formulation that combines its drug delivery technology with its client's active ingredient (4/6) |
| PharmaCom BioVet Inc. (PK:PHMB) | Unidentified research development company | A joint venture agreement for development of a compound for treatment of specific cancers for companion animals | The compound is in the family of histone deacetylase inhibitors, which binds directly to the catalytic site of the enzyme thereby potentially blocking the substrate access (4/1) |
| Prometheus Laboratories Inc.* | Rosetta Genomics Ltd. (Israel; ROSG) | License and collaboration agreement under which Rosetta grants Prometheus U.S. rights to three microRNA-based cancer diagnostic tests: miRview mets, miRview squamous and miRview meso | Rosetta will receive unspecified payments, either as milestones or research and development funding, as well as royalty payments on net sales in the U.S.; the deal also includes an $8M equity investment that Prometheus will make in Rosetta (4/13) |
| Seattle Genetics Inc. (SGEN) | Millennium (subsidiary of Takeda Pharmaceutical Co. Ltd.; Japan) | Agreement for the development of antibody-drug conjugates | Millennium gets an exclusive license to an initial antigen expressed on solid tumors, and it gains options for exclusive licenses to two other antigens upon payment of additional unspecified fees to Seattle Genetics, which is pocketing $4M up front (4/6) |
| Syntopix Group plc (UK; LSE:SYN) | Major consumer health care company | Exclusive evaluation agreement to make its library of compounds available for evaluation of their application in a number of areas | Specific terms were not disclosed, but Syntopix said it will get an up-front payment, plus further payments for any compounds subject to additional evaluation (4/14) |
| Vyteris Inc. (OTC BB:VYTR) | Zealand Pharma A/S* (Denmark) | Partnership to apply Vyteris' transdermal drug delivery system to Zealand's peptide-based drugs | The companies are planning a preclinical feasibility study; financial terms were not disclosed (4/14) |
| Notes: | |||
| * Private companies are indicated with an asterisk; ** Denotes the date the item ran in BioWorld International. | |||
| Unless otherwise notes, the trading symbols listed for public biotechnology companies are on the Nasdaq market. | |||
| AMEX = American Stock Exchange; ASX = Australian Stock Exchange; BR = Brussels Stock Exchange; CDNX = Canadian Venture Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; PK = Pink Sheets; SSE = Stockholm Stock Exchange; SWX = Swiss Stock Exchange. | |||
